This brief paper considers how such cost pressures may affect the use of angiotensin receptor blockers (ARBs) in the NHS, given that although losartan is the first drug in this class to become generic in March 2010, others will quickly follow suit. Valsartan loses patent protection in 2011, with candesartan and irbesartan following in 2012.
Indications for ARB use
Recent data indicate that candesartan is presently the most widely used ARB in England, accounting for almost a third of all ARB prescriptions. This is in part because it has been competitively priced compared with other ARBs. In average prescription cost terms, candesartan has in r

As well as continuing the amazing level of care given to patients @RBandH on the paediatric ward every week, the Vocal Beats team @rbharts charitably funded to bring the arts to patients, staff and local community- will also be regularly visiting patients @royalmarsdenNHS Thanks!